Insmed (INSM) Lifted to Hold at BidaskClub

BidaskClub upgraded shares of Insmed (NASDAQ:INSM) from a sell rating to a hold rating in a research note issued to investors on Friday, December 22nd.

INSM has been the topic of a number of other research reports. Leerink Swann boosted their target price on Insmed from $27.00 to $36.00 and gave the stock an outperform rating in a research note on Tuesday, September 5th. HC Wainwright restated a buy rating and issued a $35.00 target price on shares of Insmed in a research note on Monday, November 6th. Cowen restated a buy rating and issued a $54.00 target price on shares of Insmed in a research note on Friday, November 3rd. Zacks Investment Research cut shares of Insmed from a hold rating to a sell rating in a report on Tuesday, November 7th. Finally, ValuEngine raised shares of Insmed from a sell rating to a hold rating in a report on Wednesday, September 6th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Insmed presently has an average rating of Buy and a consensus price target of $37.50.

Shares of Insmed (NASDAQ INSM) traded up $0.40 during midday trading on Friday, hitting $31.66. The stock had a trading volume of 812,194 shares, compared to its average volume of 716,812. Insmed has a 12-month low of $11.49 and a 12-month high of $33.94. The stock has a market cap of $2,424.87, a P/E ratio of -10.18 and a beta of 1.18. The company has a debt-to-equity ratio of 0.13, a current ratio of 15.21 and a quick ratio of 15.21.

In other Insmed news, Director Donald J. Hayden, Jr. sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $32.50, for a total transaction of $487,500.00. Following the sale, the director now owns 71,131 shares of the company’s stock, valued at approximately $2,311,757.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.03% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its holdings in shares of Insmed by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 49,163 shares of the biopharmaceutical company’s stock worth $844,000 after purchasing an additional 197 shares during the period. Legal & General Group Plc increased its holdings in shares of Insmed by 2.0% in the second quarter. Legal & General Group Plc now owns 20,173 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 390 shares during the period. Parametric Portfolio Associates LLC increased its holdings in shares of Insmed by 11.2% in the second quarter. Parametric Portfolio Associates LLC now owns 16,035 shares of the biopharmaceutical company’s stock worth $275,000 after purchasing an additional 1,618 shares during the period. TIAA CREF Investment Management LLC increased its holdings in shares of Insmed by 0.9% in the second quarter. TIAA CREF Investment Management LLC now owns 213,525 shares of the biopharmaceutical company’s stock worth $3,664,000 after purchasing an additional 1,857 shares during the period. Finally, Voya Investment Management LLC increased its holdings in shares of Insmed by 9.3% in the second quarter. Voya Investment Management LLC now owns 27,960 shares of the biopharmaceutical company’s stock worth $480,000 after purchasing an additional 2,389 shares during the period. 95.28% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/14/insmed-insm-raised-to-hold-at-bidaskclub.html.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply